Connecticut lawmakers have advanced legislation to expand a pilot program designed to explore the potential of psychedelics, including psilocybin and MDMA, in therapeutic contexts. The bill, which recently passed both the House of Representatives and the Senate, now awaits the signature of Governor Ned Lamont (D). This development builds upon existing efforts to research psychedelic-assisted therapy within the state, aiming to gather more comprehensive data on these compounds in a controlled, clinical environment.
Expanding Access for Psychedelics Research
The proposed legislation, Senate Bill 191, seeks to broaden the scope of Connecticut’s existing psychedelic-assisted therapy program. Initially focused on military veterans and first responders participating in clinical trials, the expanded program would make any adult aged 18 or older eligible for participation in a clinical setting, provided they meet specific clinical eligibility criteria established by the institutional review board of the administering medical school. Researchers would continue to study these novel compounds under strict protocols.
According to Marijuana Moment, the bill would also remove language that currently mandates the program’s termination upon federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency. This change is intended to allow the state to continue its research uninterrupted and potentially qualify for federal matching funds, as noted by Representative Cristin McCarthy Vahey (D) during legislative discussions.
Rationale Behind the Expansion
The decision to expand eligibility stems partly from challenges encountered in recruiting a sufficient number of participants under the current, more restrictive framework. Representative McCarthy Vahey indicated that while veterans, first responders, and healthcare workers would remain a priority for the study, broadening the criteria would provide “leeway” to reach the target cohort of 50 participants. This adjustment is crucial for ensuring the pilot program can gather sufficient data.
Representative Nicole Klarides-Ditria (R) also voiced strong support for the legislation, emphasising the importance of “innovative research” and “evidence-based research” for addressing mental health challenges in Connecticut. The bill mandates officials to “establish, within available appropriations, a psychedelic-assisted therapy pilot program, to be administered by a medical school in the state.” This program “shall provide qualified patients with MDMA-assisted or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration (FDA),” as explicitly stated in the legislation.
Furthermore, Representative Dave Yaccarino (R), who initially voted against the original program, expressed his current support, citing studies that suggest potential for individuals experiencing trauma, such as combat veterans, firefighters, and police officers. He emphasised the importance of controlled conditions for such therapies.
Federal Context and Clinical Implications
The legislative move in Connecticut aligns with broader national discussions regarding the potential of psychedelics in therapeutic contexts. Federal officials have recently taken steps to expedite research and access in this area, including an executive order signed by President Donald Trump last month. This federal momentum underscores the growing interest in understanding how these substances might contribute to mental health care.
As previously reported by Hemp Gazette, reflecting a national trend of exploring these compounds in controlled, clinical environments, the focus remains firmly on rigorous, FDA-approved research to establish safety and efficacy for specific medical indications.
It is important to note that while the Connecticut bill specifically addresses use within a research framework, it is distinct from efforts to decriminalise psilocybin for adult recreational use, which has also seen legislative activity in the state in recent years. The current focus is on advancing medical science through structured pilot programs, ensuring patient safety and data integrity.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
